Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Wildtype”

565 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 565 results

Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43
Testing effectiveness (Phase 2)UnknownNCT02006043
What this trial is testing

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Who this might be right for
Non-small Cell Lung Cancer
Li Zhang 54
Testing effectiveness (Phase 2)Ended earlyNCT03382899
What this trial is testing

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 101
Testing effectiveness (Phase 2)Looking for participantsNCT05765812
What this trial is testing

Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Who this might be right for
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA 116
Testing effectiveness (Phase 2)UnknownNCT02515734
What this trial is testing

FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

Who this might be right for
Colorectal Cancer
Japan Clinical Cancer Research Organization 360
Early research (Phase 1)WithdrawnNCT02573220
What this trial is testing

Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer

Who this might be right for
Stage IVA Colorectal CancerStage IVB Colorectal Cancer
University of Chicago
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Testing effectiveness (Phase 2)UnknownNCT02071069
What this trial is testing

Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer

Who this might be right for
Incurable Colorectal CancerRAS-wild-type
Tianshu Liu 54
Testing effectiveness (Phase 2)Looking for participantsNCT06366347
What this trial is testing

ALPINE: Maintenance Letrozole/Abemaciclib

Who this might be right for
Endometrial CancerRecurrent Endometrial CancerTP53
Dana-Farber Cancer Institute 32
Testing effectiveness (Phase 2)UnknownNCT00964457
What this trial is testing

Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Who this might be right for
Rectum Cancer
Copenhagen University Hospital at Herlev 60
Testing effectiveness (Phase 2)Study completedNCT01075048
What this trial is testing

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Daiichi Sankyo 131
Not applicableUnknownNCT05440578
What this trial is testing

First-line Olaparib Combined With Bevacizumab Maintenance Therapy

Who this might be right for
Ovarian Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 50
Large-scale testing (Phase 3)UnknownNCT04262635
What this trial is testing

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 80
Testing effectiveness (Phase 2)Study completedNCT00885885
What this trial is testing

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Who this might be right for
Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 80
Large-scale testing (Phase 3)Study completedNCT00640471
What this trial is testing

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
NCIC Clinical Trials Group 750
Not applicableUnknownNCT05051592
What this trial is testing

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
National University Hospital, Singapore 40
Large-scale testing (Phase 3)Looking for participantsNCT06280495
What this trial is testing

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Who this might be right for
Colorectal CancerLiver Metastases
Sun Yat-sen University 156
Testing effectiveness (Phase 2)Ended earlyNCT01551693
What this trial is testing

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Dana-Farber Cancer Institute 3
Not applicableLooking for participantsNCT06850766
What this trial is testing

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Who this might be right for
IDH-Wildtype GlioblastomaGlioblastoma (GBM)
Ottawa Hospital Research Institute 50
Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Load More Results